Impacting society, creating change
Technologies developed at Ohio State are changing the world. Learn more about the startups that are currently a part of the Ohio State portfolio or download our printable catalog (as of June 30, 2019).
Search for a Startup below
CoreAccess offers a mobile application hub for healthcare providers, including physicians and trainees, to navigate their hospital systems as they learn, plan and provide care. Based on technology built at Ohio State and developed by resident physicians in the field, CoreAccess delivers a centralized application integrated with hospital systems, combining educational materials and clinical guidelines with scheduling and communication tools to improve workflow and streamline patient care.
Provides radiation biodosimetry technology intended for a minimally invasive rapid-response testing kit for an emergency. The company technology is used to assess biological exposure to radiation to enhance patient care and can also be used to assess exposure via a rapid, affordable, highly-sensitive, simple blood test that dictates care plans for emergency response in event of accidental radiation exposure.
Agile Ultrasonics is focused on enabling advancements in advanced material applications while replacing existing composite manufacturing processes. Several problems exist with established industry best practices. One is the challenge that air becomes trapped between layers of composites as they are formed. This causes critical components in armor, aerospace and automotive to be overbuilt to compensate, making them heavier and more expensive than necessary. Agile Ultrasonics eliminates 99.9% of all air pockets during the layup process.
Spot Biosystems is a biotechnology company commercializing extracellular vesicle research conducted at Ohio State. The company’s first product to market is an exosome-based liquid biopsy platform for the detection and treatment of cancer. In addition, Spot is developing a therapeutic suite of IP around gene therapy for cancer treatment, which is currently being tested in pre-clinical models.
TRIM-edicine is developing novel protein therapeutics and biologics to treat unmet medical needs, such as acute and chronic tissue injuries, muscular dystrophy, cancer, aging and diabetes. Novel therapeutic approaches involve the MG53, MG29, and ATAP proteins.